In a regulatory filing, Summit Therapeutics disclosed that its CEO Mahkam Zanganeh bought 110K shares of common stock on March 27th in a total transaction size of $411K.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Buy at Stifel
- Summit presents ivonescimab data at 2024 European Lung Cancer Congress
- Summit Therapeutics Showcases at Barclays Healthcare Conference
- SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors
- Biotech Alert: Searches spiking for these stocks today
